360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Amylin Pharmaceuticals Inc

Type: Company

Name: Amylin Pharmaceuticals Inc (Amylin Pharmaceuticals)

Nationality: United States

Fact Sheet: Fact Sheet for Amylin Pharmaceuticals

First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

/C O R R E C T I O N -- Rheingold, Valet, Rheingold, McCartney & Giuffra LLP/

In the news release, Suit filed for Pancreatic Cancer By Use of Byetta, Januvia and Janumet, issued 17-Jun-2013 by Rheingold, Valet, Rheingold, McCartney & Giuffra LLP over PR Newswire, the source was originally transmitted incorrectly as Rheingold, Valet, ... [Published TickerTech.com - Jun 17 2013]

Entities: RHEINGOLD, JANUMET, Pancreatic Cancer, Byetta

First reported Jun 13 2013 - Updated Jun 13 2013 - 1 reports

Amylin Pharmaceuticals Inc

Formation of Low Redox-Active Copper (II)-Human Amylin Complex Protects Pancreatic Cells from Amylin Toxicity

Phys. Chem. Chem. Phys. , 2013, Accepted ManuscriptDOI : 10.1039/C3CP44542A, Paper Aleksandar Jeremic, Elizabeth Lee, Emmeline Ha, Sanghamitra Singh, Linda Legesse, Sana Ahmad, Robert DonaldsonHuman amylin-derived oligomers and aggregates are believed ... [Published RSC - Jun 13 2013]

Entities: Amylin Pharmaceuticals Inc, Toxicity, Copper

First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

NOVO NORDISK A/S

Novo Nordisk Is An Undervalued Industry Leading Healthcare Company

RECOMMENDATIONWe have increased our rating on Novo-Nordisk (NVO) Class B ADRs from Accumulate to Strong Buy and increasing our Fair Value share price to $213, which represents 23% discount to the price of NVO's shares. We expect to see the company generate ... [Published Seeking Alpha - Jun 12 2013]

Entities: Insulin, Victoza, NOVO NORDISK A/S, Amylin Pharmaceuticals Inc

First reported Jun 11 2013 - Updated Jun 11 2013 - 7 reports

Former Bristol-Myers exec admits guilt in insider trading case

Robert Ramnarine bought up stock in companies he knew Bristol-Myers was purchasingA former Bristol-Myers executive is facing hefty fines and decades behind bars for insider trading.Robert Ramnarine, who worked for the company in various senior roles, ... [Published Inside Counsel - Jun 11 2013]

Entities: Bristol-Myers Squibb Company, Insider Trading, Amylin Pharmaceuticals Inc, Securities Fraud, Takeover

First reported Jun 07 2013 - Updated Jun 07 2013 - 1 reports

Gilead Sciences Inc

22nd Annual Report: Top 100 Biotechnology Companies

Biotech industry growth is bolstered by increased R&D spending, an upswing of approved first-in-class medicines, elevated Wall Street valuations, and continued forging of pipeline alliances with Big Pharma.By Andrew Humphreys (andrew.humphreys@ubm.co ... [Published Pharma Live - Jun 07 2013]

Entities: Biotechnology, MacroGenics Inc, Drugs, Gilead Sciences Inc, Multiple Sclerosis

First reported Jun 06 2013 - Updated Jun 07 2013 - 1 reports

Bristol-Myers Squibb Company

Priority Review for AZN/BMY Drug Zacks

AstraZeneca (AZN) and partner Bristol-Myers Squibb Company (BMY) recently announced that the US Food and Drug Administration (:FDA) has accepted the Biologics License Application (:BLA) for their pipeline candidate, metreleptin.The FDA has granted priority ... [Published Yahoo! Finance - Jun 06 2013]

Entities: Bristol-Myers Squibb Company, AstraZeneca PLC, Drugs, FDA Food & Drug Administration

First reported Jun 05 2013 - Updated Jun 05 2013 - 1 reports

FDA Food & Drug Administration

FDA gives priority review status to BMS/ AZ's metreleptin

Former obesity prospect has potential in the rare disease lipodystrophyA Bristol-Myers Squibb (BMS) drug abandoned as an obesity therapy looks set to find a new lease of life treating the rare disease lipodystrophy.The US FDA has granted priority review ... [Published PMLive - Jun 05 2013]

Entities: FDA Food & Drug Administration, Amylin Pharmaceuticals Inc, Obesity

First reported Jun 04 2013 - Updated Jun 05 2013 - 2 reports

Bristol-Myers Squibb and AstraZeneca announces priority review by US FDA of Metreleptin

Biopharmaceutical companies Bristol-Myers Squibb Company (NYSE:BMY) and AstraZeneca (NYSE:AZN) announced on Tuesday that the US Food and Drug Administration (FDA) has accepted and granted a Priority Review designation for the Biologics License Application ... [Published Individual.com - Jun 05 2013]

Entities: Bristol-Myers Squibb Company, FDA Food & Drug Administration, AstraZeneca PLC

First reported Jun 03 2013 - Updated Jun 04 2013 - 1 reports

AstraZeneca plc (ADR) (AZN): This Pharma Company Is Making the Right Moves

Mergers and acquisitions appear to be continuously reshaping the pharmaceuticals industry. One of the latest initiatives involved British drug maker AstraZeneca plc (ADR) (NYSE:AZN) , which announced this May 28 that a definitive agreement has been reached ... [Published InsiderMonkey.com - Jun 03 2013]

Entities: AstraZeneca PLC, Omthera Pharmaceuticals Inc, Bristol-Myers Squibb Company

First reported May 30 2013 - Updated May 30 2013 - 2 reports

Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, and The Drakulich Firm, based in San Diego, have filed a lawsuit on behalf of an Arkansas man who developed pancreatic cancer and resulting ... [Published Bio-Medicine - May 30 2013]

Entities: Byetta, Pancreatic Cancer, Drugs, Diabetes

First reported May 26 2013 - Updated May 26 2013 - 1 reports

Market Report, "Amylin Pharmaceuticals, Inc. - Strategic SWOT Analysis Review", published

(live-PR.com) - Amylin Pharmaceuticals, Inc. (Amylin), subsidiary of Bristol-Myers Squibb, is a biopharmaceutical company. It discovers, develops and commercializes medicines for the treatment of diabetes, obesity and other metabolic diseases. The marketed ... [Published Live-PR.com - May 26 2013]

Entities: Amylin Pharmaceuticals Inc, SWOT Analysis, SYMLIN, Exenatide, Byetta

First reported May 24 2013 - Updated May 24 2013 - 1 reports

Amylin Pharmaceuticals, Inc.: New Amylin Pharmaceuticals, Inc. company profile published

Amylin Pharmaceuticals, Inc. (Amylin Pharmaceuticals) is a biopharmaceutical company principally engaged in discovery, development and commercialization of medicines for the treatment of diabetes, obesity and other metabolic diseases. The marketed products ... [Published TransWorldNews - May 24 2013]

Entities: Amylin Pharmaceuticals Inc, SYMLIN, Diabetes

Quotes

"From our examination of the data, it appears to us that there has been over promotion and under warning by the sellers of these and other drugs in the incretin category" says Paul D Rheingold, senior partner in the law firm. The firm specializes in representing persons injured by drugs and medical devices...

/C O R R E C T I O N -- Rheingold, Valet, Rheingold, McCartney & Giuffra LLP/ [Published TickerTech.com - Jun 17 2013]

...the bet, like for Momenta Pharmaceuticals when he shorted the company before the FDA delayed approval of Momenta's generic version of Sanofi "s Lovenox in 2007 and then went long when the drug was finally approved in 2010. The big profits came when most investors weren't expecting approvals. Liang's biggest gain came from approval of Vanda Pharmaceuticals " Fanapt after the surprise approval . No one saw that one coming

White Collar Criminals Love Biotech Stocks [Published EquityJungle - v0.1 - Jun 15 2013]

...week for the BritishBritish Medical Journal (BMJ) on the safety of incretin-based therapies, the journal's editor Dr Fiona Godlee commented that "instead of engaging in open debate about legitimate and important scientific questions, the manufacturers have been unwilling to share their data [and] patients and doctors have not been kept properly informed about the uncertainties surrounding these drugs."

US charity calls for release of diabetes drug data [Published PMLive - Jun 14 2013]

In mid-March 2013 we wrote this article, "Emerging Drug Safety Issue: Possible Increased Risk Of Pancreatic Cancer With Byetta, Januvia, And Victoza -- Little Is Known About Long-Term Effects" , which has received alot of attention since then, especially recently, due to the growing controversy about whether these relatively new type diabetes...

Cancer of The Pancreas: Possible Side Effect For Diabetics Who Use Byetta, Januvia, Or Victoza? [Published Drug Injury Watch - Jun 12 2013]

More Content

sort by: Date \| Relevance
ADA/JDRF Type 1 Diabetes Sourcebook, Excerpt #4... [Published Diabetes in Control - Jun 17 2013]
In Depth. Diabetes. Medication [Part 3] [Published Able Magazine - Jun 17 2013]
/C O R R E C T I O N -- Rheingold, Valet, Rhein... [Published TickerTech.com - Jun 17 2013]
Suit filed for Pancreatic Cancer By Use of Byet... [Published FinanzNachrichten.de - Jun 17 2013]
White Collar Criminals Love Biotech Stocks [Published EquityJungle - v0.1 - Jun 15 2013]
Amylin Pharmaceuticals Partnering 2005-2013 - n... [Published TransWorldNews - Jun 15 2013]
US charity calls for release of diabetes drug data [Published PMLive - Jun 14 2013]
East Coast Life Sciences Roundup: Agios, Ludwig... [Published Xconomy - Jun 14 2013]
Clovis Oncology Welcomes Two New Directors to i... [Published Stockwatch - Jun 13 2013]
Formation of Low Redox-Active Copper (II)-Human... [Published RSC - Jun 13 2013]
Cancer of The Pancreas: Possible Side Effect Fo... [Published Drug Injury Watch - Jun 12 2013]
Domain Associates Promotes Shah to Partner [Published PE Hub News - Jun 12 2013]
Domain Associates Announces Promotion of Nimesh... [Published Michigan Live - Jun 12 2013]
Novo Nordisk Is An Undervalued Industry Leading... [Published Seeking Alpha - Jun 12 2013]
Former Bristol-Myers exec admits guilt in insid... [Published Inside Counsel - Jun 11 2013]
Philly connection to guilty plea by Bristol-Mye... [Published Philly.com - Jun 11 2013]
Former Bristol-Myers Exec Pleads Guilty To Insi... [Published Pharmalot - Jun 11 2013]
East Brunswick Man Confesses to Insider Trading... [Published East Brunswick Patch - Jun 11 2013]
Jail looms for former B-MS exec guilty of insid... [Published Pharma Times - Jun 11 2013]
Has pancreatic damage from glucagon suppressing... [Published PharmaGossip - Jun 11 2013]
Bristol-Myers Squibb Exec Pleads Guilty [Published Corporate Crime Reporter - Jun 11 2013]
UPDATE 1-Former Bristol-Myers executive admits ... [Published Big News Network - Jun 11 2013]
AstraZeneca to pay up to $1.15 billion for Pear... [Published Individual.com - Jun 10 2013]
AstraZeneca to pay up to $1.15B for Pearl [Published Individual.com - Jun 10 2013]
Former Bristol-Myers executive admits to inside... [Published 4 Traders - Jun 10 2013]
Ex-Bristol-Myers executive admits to insider trade [Published TD Ameritrade - Jun 10 2013]
Bristol-Myers squibb executive admits insider t... [Published United States Department of Justice - Jun 10 2013]
BRISTOL MYERS SQUIBB CO.: Former Bristol-Myers ... [Published 4 Traders - Jun 10 2013]
Recently released market study: Affibody AB - P... [Published Live-PR.com - Jun 10 2013]
22nd Annual Report: Top 100 Biotechnology Compa... [Published Pharma Live - Jun 07 2013]

Blogs

sort by: Date \| Relevance
White Collar Criminals Love Biotech Stocks [Published EquityJungle - v0.1 - Jun 15 2013] Filed under: Investing It's understandably very tempting for people with inside information to trade biotech stocks. With the potential for overnight doubles and triples after binary events, there's quick money to be made. They shouldn't. It's illegal. ...
Cancer of The Pancreas: Possible Side Effect Fo... [Published Drug Injury Watch - Jun 12 2013] Diabetes Doctors And Drug Safety Watchdog Group Express More Concern Than Ever Following June 2013 BMJ Medical Journal Article (Posted by Tom Lamb at DrugInjuryWatch.com ) In mid-March 2013 we wrote this article, "Emerging Drug Safety Issue: ...
Former Bristol-Myers Exec Pleads Guilty To Insi... [Published Pharmalot - Jun 11 2013] A former Bristol-Myers Squibb executive pleaded guilty to insider trading for buying stock options in three drugmakers that were targeted for acquisition, which yielded more than $311,000 in profits. Robert Ramnarine, 46, a former executive director ...
Has pancreatic damage from glucagon suppressing... [Published PharmaGossip - Jun 11 2013] BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f3680 (Published 10 June 2013)Cite this as: BMJ 2013;346:f3680 Article Related content Article metrics Deborah Cohen, investigations editorAuthor Affiliations dcohen@bmj.com Incretin mimetics have been ...
A Hundred Jobs Here, A Hundred Jobs There: More... [Published Pharmalot - Apr 10 2013] As the pharmaceutical industry continues to contract, keeping track of the number of people thrown overboard is a challenging exercise, especially as the largest drugmakers eliminate jobs by the thousands in successive waves. Consequently, it can be ...

Press Releases

sort by: Date \| Relevance
BioMed Realty Trust Appoints Former Amylin Pres... [Published Financial Services - Jan 04 2013]
Takeda Announces Mutual Termination of Amylin /... [Published PR Newswire: Health - Dec 24 2012]